Blana, A. and Robertson, C. N. and Brown, S. C. W. and Chaussy, C. and Crouzet, S. and Gelet, A. and Conti, G. N. and Ganzer, R. and Pasticier, G. and Thuroff, S. and Ward, J. F. (2012) Complete high-intensity focused ultrasound in prostate cancer: outcome from the @-Registry. PROSTATE CANCER AND PROSTATIC DISEASES, 15 (3). pp. 256-259. ISSN 1365-7852,
Full text not available from this repository. (Request a copy)Abstract
BACKGROUND: To analyze data on patients with localized prostate cancer who were treated with complete high-intensity focused ultrasound (HIFU) prospectively captured within a voluntary HIFU user database (@-Registry). METHODS: The @-Registry includes data from consecutive patients treated with Ablatherm (EDAP-TMS) HIFU at nine European Centres during the period 1994 and 2009. For this analysis, the data repository was reviewed for information on patients with localized prostate cancer (T1 - T2) treated with complete (whole-gland) HIFU on the basis of an anterior-posterior prostate height of <= 24 mm and a treated volume > 120% of the prostate volume. Patients were regularly followed with PSA measurement and biopsy. Biochemical failure was defined for this study as PSA nadir + 2 ng ml(-1) (Phoenix definition). Disease-free survival was based on a biopsy, retreatment and biochemical data. Patients were risk group-stratified using the D'Amico classification system. RESULTS: The median follow-up was 2.8 years for the 356 patients included in the analysis. The majority could be classified as either low (44.9%) or intermediate risk (39.6%); 14.6% patients were classified as high risk. The median (mean, s.d.) PSA nadir was 0.11 ng ml(-1) (0.78 and 3.6), achieved at a mean (s.d.) of 14.4 (11.6) weeks after HIFU. Follow-up biopsies on 226/356 (63.5%) patients revealed an overall negative biopsy rate of 80.5% (182/226); there was no statistically significant difference in positive biopsy rate by risk group-stratification. Actuarial freedom from biochemical recurrence at 5 and 7 years according to the Phoenix definition was 85% and 79%, respectively. Disease-free progression rates at 5 and 7 years were 64% and 54%, respectively. CONCLUSIONS: Whole-gland prostate HIFU as primary monotherapy for localized prostate cancer achieves a recurrence-free survival in short-term analysis as assessed by prostate biopsy and serum PSA endpoints in a majority of patients.
| Item Type: | Article |
|---|---|
| Uncontrolled Keywords: | BIOCHEMICAL FAILURE; TRANSRECTAL HIFU; biochemical failure; biopsy; high-intensity focused ultrasound; PSA |
| Subjects: | 600 Technology > 610 Medical sciences Medicine |
| Divisions: | Medicine > Lehrstuhl für Urologie |
| Depositing User: | Dr. Gernot Deinzer |
| Date Deposited: | 06 May 2020 08:50 |
| Last Modified: | 06 May 2020 08:50 |
| URI: | https://pred.uni-regensburg.de/id/eprint/18187 |
Actions (login required)
 |
View Item |
